Author

Y. Collette

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

R. Castellano· 3 shared X. Morelli· 3 shared A. Goubard· 2 shared A. Restouin· 2 shared C. Fauriat· 2 shared E. Pasquier· 2 shared G. David· 2 shared J. Fares· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. Castellano

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Downregulation of stromal syntenin sustains AML development

R. Leblanc, R. Ghossoub, A. Goubard, R. Castellano, J. Fares, L. Camoin, S. Audebert, M. Balzano, B. Boutayeh, C. Fauriat, N. Vey, J.-P. Borg, Y. Collette, M. Aurrand-Lions, G. David, P. Zimmermann

This study shows that reduced stromal syntenin in bone marrow stromal cells promotes AML aggressiveness by enhancing AML cell survival and protein synthesis through endoglin upregulation.

bioRxiv · Feb 15, 2023Cancer Biology

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

K. Carrasco, C. Montersino, C. Derviaux, M. Saez-Ayala, L. Hoffer, A. Restouin, R. Castellano, J. Casassa, P. Roche, E. Pasquier, S. Combes, X. Morelli, Y. Collette, S. Betzi

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

bioRxiv · Dec 13, 2021Cancer Biology

A syntenin-deficient microenvironment educates AML for aggressiveness

R. Leblanc, J. Fares, A. Goubard, R. Castellano, L. Camoin, M. Balzano, R. Ghossoub, B. Bou-Tayet, C. Fauriat, N. Vey, J.-P. Borg, Y. Collette, M. Aurrand-Lions, G. David, P. Zimmermann

This study shows that syntenin-deficiency in the bone marrow microenvironment promotes AML aggressiveness by enhancing cell survival through autophagy and protein synthesis.

bioRxiv · Jan 6, 2021 · PreprintCancer Biology

Synergy and allostery in ligand binding by HIV-1 Nef

A. Aldehaiman, A. A. Momin, A. Restouin, L. Wang, X. Shi, S. Aljedani, S. Opi, A. Lugari, U. F. S. Hameed, L. Ponchon, X. Morelli, M. Huang, C. Dumas, Y. Collette, S. T. Arold

This study investigates how HIV-1 Nef's flexible regions interact with its core domain to influence SH3 domain selectivity and identifies few human proteins with similar binding properties.

bioRxiv · Nov 5, 2020Biophysics

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology